For instance, ICIs could reverse T-cell exhaustion in autoimmune diseases with underlying viral infections, while TNFSF agonists like TNFR2 or CD40 could enhance the tolerogenic capacity of immune cells. Here, TNFRSF1B is linked to autoimmune disease.